Harrow’s Iheezo Gets FDA Approval for Ocular Surface Anesthesia

Harrow and Sintetica said the FDA approved Iheezo 3% for ocular surface anesthesia.

• Harrow has accelerated market access strategy to support a commercial launch date ahead of its previously planned launch in May 2023
• Iheezo represents the first approved use in the U.S. ophthalmic market of chloroprocaine hydrochloride and the first branded ocular anesthetic approved for the U.S. ophthalmic market in nearly 14 years, according to Harrow

NOTE

• Harrow Health Inc. rose 1.8% to $7.75 as of 1:52 p.m. New York time before trading was halted
  • The average 12-month price target of $16.63 is 114.5% above the current price
  • 4 ...